Abstract
Therapy with an angiotensin‐converting enzyme (ACE) inhibitor is established for reducing excessive blood pressure, reducing mortality in patients with congestive heart failure (CHF), preventing the development of CHF in patients with asymptomatic left ventricular (LV) dysfunction, and preventing death and CHF when initiated early after the onset of acute myocardial infarction (MI). Although these benefits have been attributed largely to hemodynamic mechanisms, recent preclinical and clinical evidence reveal ACE inhibition as potent in preventing ischemic events and in blocking an array of ischemic processes, including atherogenesis. A major contributor to this new evidence is the large, placebo‐controlled Heart Outcomes Prevention Evaluation (HOPE) trial, which found that the ACE inhibitor ramipril (10 mg daily) prevented MI and other ischemic events in patients with a broad range of cardiovascular (CV) risks (including coronary artery disease, stroke, peripheral vascular disease, or diabetes plus one additional risk factor) but no LV dysfunction or history of heart failure at baseline. The data from the HOPE trial suggest a greatly expanded role for ramipril in the prevention and management of CV disease.
Keywords: angiotensin‐converting enzyme inhibitors; ischemia; congestive heart failure; left ventricular dysfunction; ramipril; diabetes, stroke
Full Text
The Full Text of this article is available as a PDF (691.7 KB).
References
- 1. Borghi C, Ambrosioni E: Evidence‐based medicine and ACE inhibition. J Cardiovasc Pharmacol 1998; 32 (suppl 2): S24–S35 [DOI] [PubMed] [Google Scholar]
- 2. Ferrari R: Effect of ACE inhibition on myocardial ischaemia. Eur Heart J 1998; 19 (suppl J): J30–J35 [PubMed] [Google Scholar]
- 3. The Heart Outcomes Prevention Evaluation Study Investigators : Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. N Engl J Med 2000; 342: 145–153 [DOI] [PubMed] [Google Scholar]
- 4. Parmley WW: Evolution of angiotensin‐converting enzyme inhibition in hypertension, heart failure, and vascular protection. Am J Med 1998; 105: 27S–31S [DOI] [PubMed] [Google Scholar]
- 5. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators : Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–828 [PubMed] [Google Scholar]
- 6. Køber L, Torp‐Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm J, for the Trandolapril Cardiac Evaluation (TRACE) Study Group : A clinical trial of the angiotensin‐converting‐enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–1676 [DOI] [PubMed] [Google Scholar]
- 7. Pitt B: Regression of left ventricular hypertrophy in patients with hypertension: Blockade of the renin‐angiotensin‐aldosterone system. Circulation 1998; 98: 1987–1989 [DOI] [PubMed] [Google Scholar]
- 8. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH: Association of the renin‐sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098–1104 [DOI] [PubMed] [Google Scholar]
- 9. Remme WJ: Bradykinin‐mediated cardiovascular protective actions of ACE inhibitors: A new dimension in anti‐ischaemic therapy? Drugs 1997; 54 (suppl 5): 59–70 [DOI] [PubMed] [Google Scholar]
- 10. Finta KM, Fischer MJ, Lee L, Gordon D, Pitt B, Webb RC: Ramipril prevents impaired endothelium‐dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis 1993; 100: 149–156 [DOI] [PubMed] [Google Scholar]
- 11. The HOPE (Heart Outcomes Prevention Evaluation) Study : The design of a large, simple randomized trial of an angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE Study Investigators. Can J Cardiol 1996; 12: 127–137 [PubMed] [Google Scholar]
- 12. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G, for the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) : Renal function and requirement for dialysis in chronic nephropathy patients on long‐term ramipril: REIN follow‐up trial. Lancet 1998; 352: 1252–1256 [DOI] [PubMed] [Google Scholar]
- 13. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin‐converting‐enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–616 [DOI] [PubMed] [Google Scholar]
- 14. Carlsson PO, Berne C, Jansson L: Angiotensin II and the endocrine pancreas: Effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41: 127–133 [DOI] [PubMed] [Google Scholar]
- 15. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary heart disease. Part 2, Short‐term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–828 [DOI] [PubMed] [Google Scholar]
- 16. Fox KM, Henderson JR, Bertrand ME, Ferrari R, Remme WJ, Simoons ML: The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998; 19 (suppl J): J52–J55 [PubMed] [Google Scholar]
- 17. Pitt B, Konstam MA: Overview of angiotensin U‐receptor antagonists. Am J Cardiol 1998; 82: 47S–49S [DOI] [PubMed] [Google Scholar]
- 18. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM: Inhibition of early atherogenesis by losartan in monkeys with diet‐induced hypercholesterolemia (see comments). Circulation 2000; 101: 1586–1593 [DOI] [PubMed] [Google Scholar]
- 19. McCormick LS, Black DM, Waters D, Brown WV, Pitt B: Rationale, design, and baseline characteristics of atrial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT). Am J Cardiol 1997; 80: 1130–1133 [DOI] [PubMed] [Google Scholar]
- 20. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Tide LM, Eisenberg D, Shurzinske L, McCormick LS, for the Atorvastatin versus Revascularization Treatment Investigators : Aggressive lipid‐lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70–76 [DOI] [PubMed] [Google Scholar]
- 21. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM, for the ALLHAT Research Group : Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9: 342–360 [DOI] [PubMed] [Google Scholar]